Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has granted orphan drug designation to the investigational remedy, cintredekin besudotox, for glioblastoma multiforme, in...
Amongst sufferers with domestically recurrent inoperable or metastatic triple-negative breast most cancers for whom immunotherapy was not a therapy choice, therapy with...
Medical trial outcomes have proven that amongst sufferers with domestically superior or metastatic EGFR-mutated non-small cell lung most cancers (NSCLC), first-line remedy...
October is Breast Most cancers Consciousness Month, a time devoted to growing understanding of the illness, selling early detection, and supporting these...
